Establishment of MHC humanized mouse and its application for drug development

• Project/Area Number: 18K06047
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 42040:Laboratory animal science-related
• Research Institution: Tokyo Metropolitan Institute of Medical Science
• Principal Investigator: SUZUKI Teruhiko 公益財団法人東京都医学総合研究所, 基礎医科学研究分野, 主席研究員 (70621027)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Project Status: Completed (Fiscal Year 2021)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 染色体工学

Outline of Final Research Achievements

The amino acid sequences of major histocompatibility gene complex (MHC) proteins, which present antigens derived from pathogens such as viruses, differs in sequence among species, limiting evaluation of biopharmaceuticals such as vaccines using mice. However, humanization of many MHC genes is technically difficult. In this study, we attempted to establish MHC humanized mice.

Academic Significance and Societal Importance of the Research Achievements

本計画ではMHCヒト化マウスの作製を目標として研究を実施した。ヒトと同様の抗原提示能を持つMHCヒト化マウスが作製できれば、ワクチンなどの医薬品開発の促進に大きく貢献できると期待される。